Ipamorelin (IPA)

Growth Hormone Clinical trials

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively stimulates GH release with minimal effects on cortisol, prolactin, and appetite. Developed by Novo Nordisk, Ipamorelin is often considered the "cleanest" GHRP due to its highly selective action on growth hormone release without significant side effects on other hormonal axes. The peptide binds to the ghrelin receptor (GHS-R1a) but produces a GH release profile more similar to natural GHRH stimulation. Ipamorelin has a favorable safety profile and produces consistent, dose-dependent GH release, making it popular for research applications where specific GH stimulation is desired.

Key Data

Research Status
Clinical trials
Half-Life
2 hours
Administration
Subcutaneous injection
Typical Dosage
100-300 mcg
Molecular Weight
711.9 Da
Molecular Formula
C38H49N9O5

Mechanism of Action

Selective GHRP receptor agonist, mimics ghrelin to stimulate pituitary GH release.

Reported Benefits

All information is presented for Research Use Only (RUO). Not medical advice.

← All Peptides Dosing Calculator Community Forum Home